New Nubz Chew Treats from Nylabone Add a Burst of Flavor to the Dog Days of Summer
Nubz® Flavor Bursts chew treats are now available on Amazon.com, Chewy.com, and Walmart.com, ready to add a flavorful new twist to your dog's summer routine.
Share
Made with real cheddar cheese and irresistible bacon flavor, these natural chew treats are crafted using innovative technology that encapsulates savory flavor bursts throughout each chew, not just on the surface. They're also the newest wheat-free and corn-free addition to the Nubz® collection—perfect for providing grain-sensitive dogs the excitement they deserve in their treats.
'Summer is all about embracing fun and indulging in bold flavors, and Flavor Bursts chew treats deliver it all in one mouthwatering yet guilt-free reward,' said Glen S. Axelrod, President and CEO of Nylabone Products. 'They combine everything pet parents and dogs love about Nubz—natural, real ingredients; irresistible flavor; and USA-made quality—and leave out the corn and wheat, making them an accessible treating option for dogs with dietary needs.'
Crafted with a highly digestible potato starch recipe, Nubz® Flavor Bursts contain no artificial preservatives, colors, or fillers. They also feature the brand's namesake dental textures to promote healthy teeth and gums, can easily break in half for smaller treats, and are proudly made in the USA.
Nubz® Flavor Bursts chew treats are now available on Amazon.com, Chewy.com, and Walmart.com, ready to add a flavorful new twist to your dog's summer routine.
About Nylabone
Nylabone, a leader in healthy chewing since 1955, crafts high-quality chew toys, tasty chew treats, exciting play toys, and innovative dental solutions. A family-founded company, Nylabone has a history of helping pet parents take the best possible care of their dogs. They are committed to developing world-class solutions for destructive chewing, separation anxiety, dental health, and more, helping dogs live fuller, happier lives. Recommended by veterinarians, Nylabone® products encourage a positive relationship between humans and their furry best friends. To put it simply, Nylabone Chews Best! TM For more information, visit www.nylabone.com. Nylabone is a brand owned by TFH Publications, Inc. TFH Publications, Inc. is a subsidiary of California-based Central Garden & Pet Company (NASDAQ: CENT) (NASDAQ: CENTA) and has been a leader in responsible animal care for over 70 years.
About Central Garden & Pet
Central Garden & Pet Company (NASDAQ: CENT) (NASDAQ: CENTA) understands that home is central to life and has proudly nurtured happy and healthy homes for over 45 years. With fiscal 2024 net sales of $3.2 billion, Central is on a mission to lead the future of the pet and garden industries. The Company's innovative and trusted products are dedicated to helping lawns grow greener, gardens bloom bigger, pets live healthier, and communities grow stronger. Central is home to a leading portfolio of more than 65 high-quality brands including Amdro®, Aqueon®, Cadet®, C&S®, Farnam®, Ferry-Morse®, Four Paws®, Kaytee®, Nylabone® and Pennington®, strong manufacturing and distribution capabilities, and a passionate, entrepreneurial growth culture. Central is based in Walnut Creek, California, with over 6,000 employees, primarily across North America. Visit www.central.com to learn more.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
Jackson Healthcare Named to PEOPLE Companies That Care List for Second Consecutive Year
ATLANTA--(BUSINESS WIRE)-- Jackson Healthcare ®, one of the nation's premier providers of healthcare workforce services, today announced its second consecutive appearance on the PEOPLE ® Companies that Care list published by PEOPLE and Great Place To Work ®. This distinction highlights and celebrates businesses that lead with care for their people, local communities and the world. 'Being named again to the PEOPLE Companies that Care list is a testament to our deeply rooted company mission and values,' said Shane Jackson, president of Jackson Healthcare. 'One of our core values, Others First, guides us in putting people at the center of everything we do. We prioritize caring for our team and empowering them to make a meaningful impact through their work.' 'This recognition also reflects our deep commitment to providing a hand up in the communities in which we live, work and serve,' added Jackson. 'Through our LoveLifts community impact platform, we partner with over 450 nonprofit organizations worldwide to improve access to healthcare and enhance the wellbeing of young people. This recognition from PEOPLE and Great Place To Work honors the passion and purpose of our people within our organization and beyond, and I could not be more proud.' 'Businesses are vital pillars in the communities where they operate,' stated Michael C. Bush, CEO of Great Place To Work ®. 'Caring for your people and your community isn't something you do after you build a successful business; it's how to make your business successful.' The PEOPLE Companies that Care list is compiled using data from the Great Place To Work Trust Index ™ Survey, which measures whether all employees have a consistently positive experience at work, regardless of background or role. Companies that earn this recognition also submit a narrative with qualitative and quantitative insights to provide a complete picture of how their organizations care for their employees, communities and planet. To be considered for the list, companies must also be Great Place To Work ® Certified ™. 'Witnessing the innovative spirit with which these companies invest in their employees, communities and the world is truly invigorating,' added Charlotte Triggs, PEOPLE GM and editor-in-chief. 'Their commitment reflects our mission, to feature what happens when ordinary people do extraordinary work.' In addition to being on the 2025 PEOPLE Companies that Care list, Jackson Healthcare is on the 2025 Fortune 100 Best Companies to Work For ® list, as well as it's most recent Best Workplaces for Women ™ and Best Workplaces in Health Care ™ lists. The organization has also been Great Place To Work Certified for nearly a decade. About the PEOPLE Companies That Care List Great Place To Work selected the 2025 PEOPLE Companies that Care list by gathering and analyzing over 1.3 million confidential survey responses from companies representing more than 8.4 million U.S. employees at Great Place To Work Certified organizations. Of those, more than 1 million responses came from employees at companies eligible for the list, and these rankings are based on that feedback. Company rankings are derived from 60 employee experience questions within the Great Place To Work Trust Index ™ Survey and essays submitted by participating companies. Read the full methodology. About PEOPLE Launched in 1974, PEOPLE revolutionized personality journalism by celebrating the extraordinary in ordinary people and the ordinary in extraordinary people. Over 50 years later, it remains a trusted authority on human interest and celebrity news, reaching over 100 million consumers through digital platforms, video, social media, the PEOPLE app and print. Renowned for iconic issues such as Sexiest Man Alive and World's Most Beautiful, PEOPLE delivers breaking entertainment news, exclusive red carpet access, and in-depth reporting on today's most compelling newsmakers. With a legacy of award-winning journalism and photojournalism, PEOPLE, a brand of People Inc., is ranked No. 1 in the entertainment news category by Comscore. About Great Place To Work As the global authority on workplace culture, Great Place To Work brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Its proprietary platform and Great Place To Work Model ™ help companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified or receiving recognition on a coveted Best Workplaces ™ List. Follow Great Place To Work on LinkedIn, Twitter, and Instagram, or visit and sign up for the newsletter to learn more. About Jackson Healthcare Jackson Healthcare ® is one of the nation's premier providers of healthcare workforce services and the parent company of more than 20 businesses that share a common mission: to improve the delivery of patient care and the lives of everyone it touches. Powered by expert associates and tens of thousands of clinician providers, it delivers quality care when and where it's needed in communities across the country – helping thousands of health systems, hospitals and medical facilities serve over 20 million patients a year. Jackson Healthcare – which marks its 25 th anniversary in 2025 – is Great Place To Work ® Certified ™ and appears on the latest Forbes list of America's Top Private Companies; Fortune lists of the 100 Best Companies to Work For ® and Best Workplaces in Health Care ™; and PEOPLE ® list of Companies that Care. Learn more at
Yahoo
4 hours ago
- Yahoo
Summit Therapeutics Advances as Trial Outcomes and New Collaboration Drive Optimism
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 11 Best Short Squeeze Stocks to Buy Now. Following mixed results in the clinical trial of Ivonescimab, the company entered a new clinical collaboration with Revolution Medicines. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. The biopharma company, Summit Therapeutics Inc. (NASDAQ:SMMT) develops oncology therapies. Its lead candidate, Ivonescimab, targeting PD-1 and VEGF, is in clinical trials for non-small cell lung cancer. The Miami-based company currently holds regulatory collaborations for commercialization across multiple global regions. On May 30, 2025, Summit Therapeutics Inc. (NASDAQ:SMMT) announced mixed results from the trial of its antibody treatment for lung cancer, Ivonescimab. In a comparison study, the drug had initially performed better than Merck's Keytruda. But the latest evaluation revealed both promising and less favourable outcomes. Later, on June 30, 2025, the company entered a new clinical collaboration with Revolution Medicines to evaluate combinations of three RAS(ON) inhibitors with Ivonescimab in RAS mutant tumours. The aim is to assess the safety and efficacy of these combinations across three priority tumour types, including RAS mutant non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC). Initial study stands positive with evidence suggesting that Revolution Medicines' inhibitors in combination with a PD-1 antibody can deliver additive antitumor activity safely in patients with RAS mutant NSCLC. This has created anticipation for further therapeutic benefits with novel PD-1 bispecific inhibitors like Ivonescimab. With favorable developments triggering sharp upside movements, the company's short float of 25.63% remains attractive to short-squeeze investors. While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best REIT Stocks to Buy Right Now and 10 Stocks with Huge Catalysts on the Horizon Disclosure. None.
Business Wire
5 hours ago
- Business Wire
Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers
FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced it has received, from Statera Biopharma, two investigational new drug applications (INDs) for its lead candidate, Entolimod™. The two INDs cover the use of Entolimod to treat acute radiation syndrome, including both hematopoietic (ARS-H) and gastrointestinal (ARS-GI) sub-syndromes, and the use of Entolimod to treat advanced cancers, including as an anti-tumor agent and for conditions resulting from cancer treatments. 'Transfer of these INDs to Tivic allows us to formally engage the FDA regarding Entolimod's regulatory pathway and enables clinical trials in neutropenia, lymphocyte exhaustion, and other cancer-related conditions,' stated Tivic CEO, Jennifer Ernst. 'While the IND for advanced cancers allows exploration of Entolimod's anti-tumor activity, building on prior developments, we remain focused in the near-term on Entolimod's first indication--acute radiation syndrome.' About Entolimod Entolimod is a novel TLR5 agonist that triggers NF-kB signaling, activating antiapoptotic and cell protective mechanisms. Under the FDA's Animal Rule, Entolimod has been the subject of extensive trials for the treatment of acute radiation syndrome (ARS), and has demonstrated robust survival, enhanced GI tract recovery and improved hematopoiesis in animal models. Entolimod has been granted Fast Track Designation for ARS. Tivic also holds the exclusive rights for Entolimod for the treatment of neutropenia and has the option to license additional indications, including lymphocyte exhaustion, immunosenescence, and chronic radiation syndrome. About Tivic Tivic's dual platform strategy utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late-stage development. Tivic's bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities; changes to the company's relationship with the its partners; timing and success of clinical trials and study results; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy; regulatory requirements and pathways for approval; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 'Risk Factors,' as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
